Clinical Trial

A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).
Protocol Amendment History 25 amendments
This ClinicalTrials.gov record has been amended 25 times since 2023-06-27; most recent amendment 2026-07-17.
Status change: Recruiting → Active, Not Recruiting 2025-09-17
Status change: Active, Not Recruiting → Recruiting 2025-02-21
Status change: Recruiting → Active, Not Recruiting 2024-09-26
Trial Details
NCT Number NCT05933200
Lead Sponsor Ultragenyx Pharmaceutical Inc
Conditions Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Enrollment 69 participants
Start Date 2023-02-28
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-21